1. Cardiac resynchronization therapy in patients with congenital heart disease and systemic right ventricle
- Author
-
Sébastien Hascoët, Victor Waldmann, Magalie Ladouceur, Mikael Laredo, Nicolas Combes, Etienne Jacquemart, Laurence Iserin, Charlene Bredy, Guillaume Duthoit, Alice Maltret, Eloi Marijon, Jean-Luc Pasquié, Sylvie Di Filippo, and Francis Bessière
- Subjects
Adult ,Heart Defects, Congenital ,Male ,medicine.medical_specialty ,Ventricular Ejection Fraction ,Heart disease ,Heart Ventricles ,medicine.medical_treatment ,Cardiac resynchronization therapy ,030204 cardiovascular system & hematology ,Cardiac Resynchronization Therapy ,Cohort Studies ,Young Adult ,03 medical and health sciences ,QRS complex ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Retrospective Studies ,Heart Failure ,business.industry ,Middle Aged ,medicine.disease ,Defibrillators, Implantable ,3. Good health ,Treatment Outcome ,medicine.anatomical_structure ,Ventricle ,Heart failure ,Cohort ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Cohort study - Abstract
Although patients with systemic right ventricle (SRV) represent a significant proportion of patients with congenital heart disease (CHD) implanted with cardiac resynchronization therapy (CRT), there are limited and conflicting data in this specific patient group.We aimed to analyze outcomes of patients with SRV implanted with a CRT device.Data were analyzed from an observational, retrospective, multicenter cohort study including all patients with CHD implanted with a CRT device from 6 French centers from 2004 to 2020. Response to CRT was defined as an increase in systemic ventricular ejection fraction of ≥10% and/or an improvement in New York Heart Association functional class by at least 1 grade.A total of 85 patients with CHD were enrolled (mean age 39.8 ± 20.0 years; 55 [64.7%] males; 25 defibrillators [29.4%]), including 31 patients with SRV (36.5%) (mean age 43.9 ± 19.8 years; 16 [51.6%] males). The mean change in QRS duration after implantation was similar as compared with patients with systemic left ventricle (-46 ± 26 ms vs -35 ± 32 ms; P = .16). During a mean follow-up of 5.1 ± 3.5 years, late complications included 2 lead dysfunctions (6.5%), 3 CRT-related infections (9.7%), and 1 inappropriate implantable cardioverter-defibrillator shock (3.2%). The proportion of CRT responders at 6, 12, and 24 months were 82.6%, 80.0%, and 77.8% in patients with SRV vs 66.7%, 64.3%, and 69.6% in patients with systemic left ventricle (P = NS).In this multicenter cohort, one-third of patients with CHD implanted with a CRT device had SRV. CRT in patients with SRV was associated with a high rate of responders, comparable to that of patients with systemic left ventricle.
- Published
- 2022